Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial
Abstract
Background: Emerging concepts on the role of insulin resistance (IR) in the pathogenesis of polycystic ovary syndrome (PCOS) have driven a shift in the therapeutic approach towards interventions targeting IR. SarogLItazar as an add-on to Metformin in PolyCystic Ovary Syndrome (SLIM-PCOS) trial aims to test the efficacy and safety of saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR α/γ) agonist belonging to "glitazar" class of drugs, on top of metformin and lifestyle intervention in PCOS.
Methods: SLIM-PCOS is an investigator-initiated, randomized, open label, parallel group, superiority, clinical trial. Around 140 PCOS patients will be randomized in 1:1 ratio to either of the two study groups: Group A: tablet saroglitazar (4 mg daily) + tablet metformin (500 mg twice daily) + lifestyle intervention; and Group B: tablet metformin + lifestyle intervention. Lifestyle intervention will comprise of dietary intervention and physical activity. Treatment will be given for 24 weeks and post-treatment follow up done at 36 weeks. The primary outcome is to compare the change in serum sex hormone binding globulin (SHBG) levels at 24 weeks from baseline between the two groups. Secondary efficacy outcomes include clinical (anthropometry, hirsutism, menstrual cycles); metabolic and gonadal parameters (lipid profile, IR, ovarian hormones and androgens, metabolic syndrome); hepatic steatosis on transabdominal scan and quality of life. Safety outcomes include patient…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 140 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.